<DOC>
	<DOC>NCT02716181</DOC>
	<brief_summary>A Double-Blind Randomized Placebo-Controlled Trial to Evaluate the Efficacy of the "Атопик Soothing Cream" in Children with Mild to Moderate Atopic Dermatitis</brief_summary>
	<brief_title>Efficacy of the "Атопик Soothing Cream" in Children With Mild to Moderate Atopic Dermatitis</brief_title>
	<detailed_description>"Атопик Soothing Cream" is a lipid complex composed of barley grain, Butyrospermum Parkii and Argania Spinosa Kernel oil, in a mixture with panthenol and bisabolol. Investigators concure that combination of these substances in "Атопик Soothing Cream" will be efficacious non-steroidal treatment of Atopic Dermatiti ( AD).</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Must have clinical diagnosis of mild to moderate atopic dermatitis (AD) at both Screening and Baseline Visits, defined as IGA score of 2 or 3 ( Rothe 1996) or EASI score between 2 and 21 (Leshem 2015) Must have AD affecting &gt;5% total body surface area (TBSA) at Baseline History of AD for at least 3 months prior to Baseline Informed consent/assent in accordance with the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guideline and applicable regulations, before completing any studyrelated procedures Use of topical corticosteroids within 7 days prior to Baseline Use of systemic corticosteroids, topical calcineurin inhibitors, phototherapy (PUVA, UVB) or immunosuppressive therapy (eg, cyclosporine) within 14 days prior to Baseline Subjects that require systemic therapy for the treatment of AD Use of systemic antiinfective or antibiotic treatment within 14 days prior to Baseline Subjects who present with clinical conditions other than AD that may interfere with the evaluation (eg, generalized erythroderma, acne, Netherton's Syndrome, psoriasis) Any clinically significant skin disease other than AD Secondary infection of AD (bacterial, viral or fungal) within the skin area under study or open skin infections in any area at Baseline History of severe anxiety and/or depression; any history of suicide attempt Subjects with a history of human immunodeficiency virus (HIV) as determined by medical history Subjects who, in the opinion of the Investigator(s), would be noncompliant with the visit schedule or study procedures Participation in any other investigational trial within 6 weeks of Baseline, or during study conduct Chronic condition(s) which are either unstable or not adequately controlled Drug or alcohol abuse, mental dysfunction, or other condition limiting the subject's ability to be compliant with studyrelated procedures Any medical condition that may, in the opinion of the Investigator(s), preclude the safe administration of test article or safe participation in the study</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Atopic Dermatitis</keyword>
	<keyword>Topical therapy</keyword>
</DOC>